# Safety, Tolerability, Biological Effects and Pharmacokinetics of BIIL 284 BS in Healthy Males

> **NCT02265302** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 95 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BIIL 284 oral solution
- **DRUG:** BIIL 284 wetability improved formulation (WIF) tablets
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02265302
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-06
- **Primary completion:** 1998-12
- **Final completion:** —
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2014-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02265302

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02265302, "Safety, Tolerability, Biological Effects and Pharmacokinetics of BIIL 284 BS in Healthy Males". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02265302. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*